Neola Medical AB

Neola Medical develops Neola® — Neonatal Lung Analyzer — a class II medical device designed to advance neonatal intensive care. Our mission is to give preterm born babies a safer and stronger start in life by empowering healthcare professionals with non-invasive, continuous lung monitoring that enables instant detection of lung collapse and provides critical insights needed to make life-saving decisions. The goal is earlier intervention, improved clinical outcomes, and a new standard of care for the most fragile patients.

Anyone who was a shareholder in Neola Medical AB on the record date of June 1, 2026 has preferential rights to subscribe for shares, in relation to previous shareholdings. Anyone who is a registered shareholder on the record date shall recieve one (1) subscription right for each held share in Neola Medical AB. To subscribe for three (3) new shares at the subscription price of 1.00 SEK per share, five (5) subscription rights are needed. For subscription without subscription rights, the above registration form can be used. When subscribing via ISK/KF accounts, subscription must be made in agreement with the bank/custodian where the account is located.